USANA Health Sciences, Inc. cash flow to debt ratio of 159.64% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

USANA Health Sciences, Inc. has insufficient data to evaluate this check.

USANA Health Sciences, Inc.'s debt to equity ratio is 0.03, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

USANA Health Sciences, Inc. has insufficient data to evaluate this check.

USANA Health Sciences, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

USANA Health Sciences, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

USANA Health Sciences, Inc.'s profit margin has decreased (-80.52%) in the last year from 4.92% to 0.96%, signaling decreasing performance

USANA Health Sciences, Inc.'s short-term assets of $288.40M exceed its short-term liabilities of $128.56M

USANA Health Sciences, Inc.'s return on assets of 1.20% is lower than the 5.00% threshold, indicating inefficient asset utilization

USANA Health Sciences, Inc.'s return on equity of 1.66%, is lower than 15.00%, indicating bad performance

USANA Health Sciences, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

USANA Health Sciences, Inc. had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings

USANA Health Sciences, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

USANA Health Sciences, Inc. has a free cash flow yield of 2.23%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

USANA Health Sciences, Inc.'s yearly earnings has decreased -74.40% since last year from $42.03M to $10.76M, signaling decreasing performance

USANA Health Sciences, Inc. has insufficient data to evaluate this check.

ROIC 1.75% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

USANA Health Sciences, Inc.'s 3-year revenue CAGR of -2.51% is negative, indicating declining revenue over the past 3 years

USANA Health Sciences, Inc. had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance

USANA Health Sciences, Inc. had positive ROE in 4.00 out of 5 years, indicating consistent and reliable returns on equity

USANA Health Sciences, Inc. is overvalued relative to its fair value price of 8.64 based on Discounted Cash Flow model

USANA Health Sciences, Inc. has an earnings yield of 2.33%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

USANA Health Sciences, Inc. is undervalued relative to its fair value price of 42.18 based on EBITDA multiple model

USANA Health Sciences, Inc. has an EV/EBITDA ratio of 2.91x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

USANA Health Sciences, Inc. is undervalued relative to its fair value price of 24.62 based on Earnings Fair Value model

USANA Health Sciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

USANA Health Sciences, Inc. has a price-to-book ratio of 0.70x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

USANA Health Sciences, Inc. has a price-to-sales ratio of 0.41x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue